Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies

被引：27

作者：

Schweitzer, N. ^{[1
]}

Vogel, A. ^{[1
]}

机构：

[1] Dept Gastroenterol Hepatol & Endcrinol, D-30625 Hannover, Germany

来源：

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY | 2015年 / 29卷 / 02期

关键词：

Cholangiocarcinoma; Biliary tract cancer; Chemotherapy; Gemcitabine; Targeted therapy; ADVANCED BILIARY-TRACT; PHASE-II TRIAL; GALL-BLADDER CANCER; GALLBLADDER CARCINOMA; INTRAHEPATIC CHOLANGIOCARCINOMA; 1ST-LINE TREATMENT; 2ND-LINE TREATMENT; PLUS GEMCITABINE; BILE-DUCT; TRANSARTERIAL CHEMOEMBOLIZATION;

D O I：

10.1016/j.bpg.2015.01.002

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Cholangiocarcinomas (CCA) are rare tumors of the liver with poor prognosis. The standard of care in patients with unresectable tumors or metastatic disease is combination chemotherapy (CT) with gemcitabine and cisplatin. Targeted therapies inhibiting EGFR, VEGF, MEK and others are broadly tested in CCA but to date, the existing data from randomized and nonrandomized trials do not justify the application of small molecules outside of clinical trials. In clinical practice, many patients receive second-line CT after failure of gemcitabine/cisplatin, although there is so far no evidence to support second-line CT. This review summarizes current chemotherapy protocols and ongoing studies, including conventional chemotherapy and targeted therapies. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：345 / 353

页数：9

共 88 条

[1] Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma - A north central cancer treatment group phase II trial [J].

Alberts, SR ;

Al-Khatib, H ;

Mahoney, MR ;

Burgart, L ;

Cera, PJ ;

Flynn, PJ ;

Finch, TR ;

Levitt, R ;

Windschitl, HE ;

Knost, JA ;

Tschetter, LK .

CANCER, 2005, 103 (01) :111-118

[2] Descriptive epidemiology of cholangiocarcinoma in Italy [J].

Alvaro, Domenico ;

Crocetti, Emanuele ;

Ferretti, Stefano ;

Bragazzi, Maria Consiglia ;

Capocaccia, Riccardo .

DIGESTIVE AND LIVER DISEASE, 2010, 42 (07) :490-495

[3] Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study [J].

Andre, T. ;

Reyes-Vidal, J. M. ;

Fartoux, L. ;

Ross, P. ;

Leslie, M. ;

Rosmorduc, O. ;

Clemens, M. R. ;

Louvet, C. ;

Perez, N. ;

Mehmud, F. ;

Scheithauer, W. .

BRITISH JOURNAL OF CANCER, 2008, 99 (06) :862-867

[4] Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma:: a GERCOR study [J].

André, T ;

Tournigand, C ;

Rosmorduc, O ;

Provent, S ;

Maindrault-Goebel, F ;

Avenin, D ;

Selle, F ;

Paye, F ;

Hannoun, L ;

Houry, S ;

Gayet, B ;

Lotz, JP ;

de Gramont, A ;

Louvet, C .

ANNALS OF ONCOLOGY, 2004, 15 (09) :1339-1343

[5] Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers [J].

Bekaii-Saab, Tanios ;

Phelps, Mitch A. ;

Li, Xiaobai ;

Saji, Motoyasu ;

Goff, Laura ;

Kauh, John Sae Wook ;

O'Neil, Bert H. ;

Balsom, Stephanie ;

Balint, Catherine ;

Liersemann, Ryan ;

Vasko, Vasily V. ;

Bloomston, Mark ;

Marsh, William ;

Doyle, L. Austin ;

Ellison, Gilian ;

Grever, Michael ;

Ringel, Matthew D. ;

Villalona-Calero, Miguel A. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) :2357-2363

[6] Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial [J].

Bengala, C. ;

Bertolini, F. ;

Malavasi, N. ;

Boni, C. ;

Aitini, E. ;

Dealis, C. ;

Zironi, S. ;

Depenni, R. ;

Fontana, A. ;

Del Giovane, C. ;

Luppi, G. ;

Conte, P. .

BRITISH JOURNAL OF CANCER, 2010, 102 (01) :68-72

[7]

Burke EC, 1998, ANN SURG, V228, P385, DOI 10.1097/00000658-199809000-00011

[8] Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study [J].

Buzzoni, R. ;

Pusceddu, S. ;

Bajetta, E. ;

De Braud, F. ;

Platania, M. ;

Iannacone, C. ;

Cantore, M. ;

Mambrini, A. ;

Bertolini, A. ;

Alabiso, O. ;

Ciarlo, A. ;

Turco, C. ;

Mazzaferro, V. .

ANNALS OF ONCOLOGY, 2014, 25 (08) :1597-1603

[9] Phase II Trial of Erlotinib and Docetaxel in Advanced and Refractory Hepatocellular and Biliary Cancers: Hoosier Oncology Group GI06-101 [J].

Chiorean, Elena Gabriela ;

Yu, Menggang ;

Ramasubbaiah, Rashmi ;

Picus, Joel ;

Bufill, Jose A. ;

Tong, Yan ;

Coleman, Nicki ;

Johnston, Erica L. ;

Currie, Colleen ;

Loehrer, Patrick .

ONCOLOGIST, 2012, 17 (01) :E14-E26

[10] Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma [J].

Cho, JY ;

Paik, YH ;

Chang, YS ;

Lee, SJ ;

Lee, DK ;

Song, SY ;

Chung, JB ;

Park, MS ;

Yu, JS ;

Yoon, DS .

CANCER, 2005, 104 (12) :2753-2758

← 1 2 3 4 5 6 7 8 9 →